Quote | Aadi Bioscience Inc. (NASDAQ:AADI)
Last: | $1.505 |
---|---|
Change Percent: | 5.24% |
Open: | $1.47 |
Close: | $1.43 |
High: | $1.53 |
Low: | $1.42 |
Volume: | 43,801 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
News | Aadi Bioscience Inc. (NASDAQ:AADI)
2024-07-05 13:07:29 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of many stock market indexes used to measure performance, the Russell 2000 is composed of 2,000 small-cap companies that make up the bottom two-thirds of the Russell 3000 index. The...
Aadi Bioscience to Participate in the Jefferies Healthcare Conference PR Newswire LOS ANGELES , May 29, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapi...
Message Board Posts | Aadi Bioscience Inc. (NASDAQ:AADI)
Subject | By | Source | When |
---|---|---|---|
$AADI: That megamove in$ RXDX today........ 36 to 100 | makinezmoney | investorshub | 12/07/2022 3:03:53 PM |
whytestocks: $AADI News Article - Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Co | whytestocks | investorshangout | 10/12/2022 12:40:48 PM |
$AADI: You saw $BMY buyout $TPTX today for $76/sh | makinezmoney | investorshub | 06/03/2022 2:44:55 PM |
whytestocks: $AADI News Article - Aadi Bioscience Reports First Quarter 2022 Financial Results and P | whytestocks | investorshangout | 05/12/2022 6:10:50 PM |
$AADI: With the Whacky way this trades............ | makinezmoney | investorshub | 11/24/2021 1:08:30 PM |
News, Short Squeeze, Breakout and More Instantly...
Aadi Bioscience to Participate in the Jefferies Healthcare Conference PR Newswire LOS ANGELES , May 29, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapi...
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire nab-Sirolimus demonstrated significantly greater intratumoral drug concentration, stronger inhi...